Direxion Daily S&P Biotech Bull 3X ETF
LABU
37 hedge funds and large institutions have $58.4M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
12% more funds holding
Funds holding: 33 → 37 (+4)
4.88% more ownership
Funds ownership: 4.11% → 8.99% (+4.9%)
33% less call options, than puts
Call options by funds: $156M | Put options by funds: $231M
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
81% less capital inflows, than outflows
Capital inflows: $5.8M | Capital outflows: $31.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTS Securities
Miami,
Florida
|
+$3.34M |
| 2 |
RAM
Revere Asset Management
Dallas,
Texas
|
+$436K |
| 3 |
Jane Street
New York
|
+$368K |
| 4 |
VR
Valued Retirements
Houston,
Texas
|
+$298K |
| 5 |
Simmons Bank
Pine Bluff,
Arkansas
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jump Financial
Chicago,
Illinois
|
-$9.24M |
| 2 |
Goldman Sachs
New York
|
-$8.1M |
| 3 |
Tower Research Capital (TRC)
New York
|
-$4.09M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.36M |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
-$2.56M |
LABU Hedge Fund Activity: Q2 2026 in Review
37 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2026, worth a combined $58.4M — up 3% from $56.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LABU positions and 8 closed out — a net gain of 4 holders — while 4 added to existing stakes and 14 trimmed.
The largest buyer was GTS Securities, opening a new position worth an estimated $3.34M. The largest seller was Jump Financial, exiting entirely with an estimated $9.24M sold.
- 37 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2026, up from 33 in Q1 2026.
- Funds reported $58.4M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2026, up 3% quarter-over-quarter.
- 12 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2026 and 8 closed out, a net change of +4 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2026 was GTS Securities, an estimated $3.34M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2026 was Jump Financial, an estimated $9.24M sold.
Based on aggregated 13F filings for Q2 2026.